Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
about
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.New Pharmacotherapies in Chronic Lymphocytic Leukemia.Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
P2860
Q31056968-7D5EAA60-FBF7-4A73-8363-7A4F1DD810B1Q33436535-CF2527E3-D831-4AAF-82AA-BDB1939C9467Q37605306-C468C4BF-D868-44A8-8A69-2F82E869CD52Q39169789-B245E94B-C211-4B02-A40C-A4F9D7600794Q47887134-069E20F4-1E82-4C48-BB02-D937443277AAQ49818481-6C9F5044-3C1E-43C0-9FB6-2BF11DFDA90BQ50864223-BB380A23-3B0E-46E4-A4C2-411BF57776EA
P2860
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Safety and efficacy of differe ...... ded randomized phase II trial.
@ast
Safety and efficacy of differe ...... ded randomized phase II trial.
@en
Safety and efficacy of differe ...... ded randomized phase II trial.
@en-gb
type
label
Safety and efficacy of differe ...... ded randomized phase II trial.
@ast
Safety and efficacy of differe ...... ded randomized phase II trial.
@en
Safety and efficacy of differe ...... ded randomized phase II trial.
@en-gb
prefLabel
Safety and efficacy of differe ...... ded randomized phase II trial.
@ast
Safety and efficacy of differe ...... ded randomized phase II trial.
@en
Safety and efficacy of differe ...... ded randomized phase II trial.
@en-gb
P2093
P2860
P50
P921
P1433
P1476
Safety and efficacy of differe ...... ded randomized phase II trial.
@en
P2093
Andreas Buhler
Anne-Sophie Michallet
Asher Chanan-Khan
Brendan Purse
Clemens M Wendtner
Graeme A M Fraser
Jennie Zhang
John G Gribben
P2860
P304
P356
10.3109/10428194.2015.1128540
P577
2016-01-14T00:00:00Z